New Zealand markets close in 6 hours 47 minutes

Koninklijke Philips N.V. (PHG)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
21.23-0.30 (-1.39%)
At close: 04:00PM EDT
21.79 +0.56 (+2.64%)
After hours: 05:11PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close21.53
Open20.91
Bid20.20 x 1200
Ask26.09 x 1000
Day's range20.80 - 21.25
52-week range20.20 - 48.72
Volume1,672,507
Avg. volume2,050,786
Market cap18.665B
Beta (5Y monthly)0.84
PE ratio (TTM)37.91
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.91 (4.30%)
Ex-dividend date12 May 2022
1y target estN/A
  • GlobeNewswire

    Philips completes cancellation of 8.8 million shares

    July 4, 2022Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 8,758,455 of its shares. The cancelled shares were acquired as part of the EUR 1.5 billion share repurchase program for capital reduction purposes that was announced on July 26, 2021.Philips’ current issued share capital amounts to EUR 177,863,016.40 representing 889,315,082 common shares. As communicated earlier, Philips intends to have 19,571,218 shares delive

  • Business Wire

    Philips Signs Health Care Sector Pledge to Reduce Emissions as part of Department of Health and Human Services, White House Initiative

    CAMBRIDGE, Mass., July 01, 2022--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the company has joined an initiative created by the Department of Health and Human Services (HHS), in partnership with the White House, to address climate action through the reduction of greenhouse gas emissions. Earlier this week at the White House, Philips along with other health sector organizations and administration leaders, participated in a roundtable discussion abo

  • GlobeNewswire

    Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis

    Lung Cancer Orchestrator June 30, 2022Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has teamed up with Biodesix, Inc. (Colorado, U.S.) (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, to incorporate th